• Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board Director • Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger OPA, Yaqrit’s phase 3 treatment for hepatic...
• Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024 • Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and FDA fast track designations February 11,...
